Eton Pharmaceuticals Inc (ETON)

$3.66

+0.07

(+1.95%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Eton Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 7.02M → 7.96M (in $), with an average increase of 6.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -2.25M → -811.0K (in $), with an average increase of 178.2% per quarter

Performance

  • $3.51
    $3.68
    $3.66
    downward going graph

    4.1%

    Downside

    Day's Volatility :4.62%

    Upside

    0.54%

    downward going graph
  • $2.42
    $5.81
    $3.66
    downward going graph

    33.88%

    Downside

    52 Weeks Volatility :58.35%

    Upside

    37.01%

    downward going graph

Returns

PeriodEton Pharmaceuticals IncIndex (Russel 2000)
3 Months
-19.69%
0.0%
6 Months
-1.37%
0.0%
1 Year
3.46%
0.0%
3 Years
3.46%
-20.1%

Highlights

Market Capitalization
93.5M
Book Value
$0.6
Earnings Per Share (EPS)
-0.04
Wall Street Target Price
8.0
Profit Margin
-2.96%
Operating Margin TTM
-27.25%
Return On Assets TTM
-2.63%
Return On Equity TTM
-6.56%
Revenue TTM
31.6M
Revenue Per Share TTM
1.23
Quarterly Revenue Growth YOY
-13.900000000000002%
Gross Profit TTM
14.3M
EBITDA
-358.0K
Diluted Eps TTM
-0.04
Quarterly Earnings Growth YOY
-0.13
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.27
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Eton Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 118.58%

Current $3.66
Target $8.00

Technicals Summary

Sell

Neutral

Buy

Eton Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc
10.46%
-1.37%
3.46%
3.46%
3.46%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.15%
26.64%
50.32%
46.7%
76.15%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
1.91%
2.16%
-0.35%
14.98%
14.98%
Zoetis Inc.
Zoetis Inc.
18.72%
-3.66%
-3.75%
-2.05%
67.86%
Viatris Inc.
Viatris Inc.
-2.58%
16.97%
15.73%
-28.65%
-32.93%
Catalent, Inc.
Catalent, Inc.
-1.94%
38.79%
46.52%
-46.41%
19.01%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc
49.56
NA
NA
0.0
-0.07
-0.03
NA
0.6
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
38.49
38.49
0.44
4.06
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.37
28.37
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
33.54
33.54
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.33
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc
Buy
$93.5M
3.46%
49.56
-2.96%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.3B
76.15%
38.49
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.9B
14.98%
28.37
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$79.6B
67.86%
33.54
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-32.93%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.0B
19.01%
211.02
-28.44%

Institutional Holdings

  • Opaleye Management Inc

    9.85%

  • Vanguard Group Inc

    4.00%

  • Westside Investment Management, Inc.

    2.19%

  • Acuitas Investments, LLC

    1.92%

  • Paradigm Capital Management, Inc.

    1.17%

  • BlackRock Inc

    1.11%

Company Information

eton pharmaceuticals, inc. is a deer park, illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the u.s. food and drug administration’s 505(b)(2) regulatory pathway. our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.

Organization
Eton Pharmaceuticals Inc
Employees
30
CEO
Mr. Sean E. Brynjelsen
Industry
Health Technology

Discover More

FAQs